{"id":44775,"date":"2022-06-07T00:01:22","date_gmt":"2022-06-06T22:01:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/"},"modified":"2022-06-07T00:01:22","modified_gmt":"2022-06-06T22:01:22","slug":"new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/","title":{"rendered":"New MYLUNG Consortium Research Demonstrates Remote Pharmacist Intervention Significantly Increases Clinical Trial Enrollments in Community Oncology Setting"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nAverage monthly enrollment nearly doubled with pharmacy intervention\n<\/li>\n<li>\nRemote pharmacist easily adapted into clinic workflows in community practices\n<\/li>\n<\/ul>\n<p>THE WOODLANDS, Texas&#8211;(BUSINESS WIRE)&#8211;Results from the second phase of the broad, collaborative <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fusoncology.com%2Fan-inside-look-at-mylung%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=MYLUNG+ConsortiumTM&amp;index=1&amp;md5=b2ebaae147a9cbc1baa1d22296823720\" rel=\"nofollow noopener\" shape=\"rect\">MYLUNG Consortium<sup>TM<\/sup><\/a> research study in non-small cell lung cancer (NSCLC) were presented by <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.usoncology.com&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=The+US+Oncology+Network&amp;index=2&amp;md5=9aebb8b02231654f69377d4928dc2231\" rel=\"nofollow noopener\" shape=\"rect\">The US Oncology Network<\/a> (The Network), <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fusoncology.com%2Fphysicians%2Fclinical-trials%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=US+Oncology+Research&amp;index=3&amp;md5=9d608debd28f75748115efdb3534ed30\" rel=\"nofollow noopener\" shape=\"rect\">US Oncology Research<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ontada.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Ontada&amp;index=4&amp;md5=df033db3d6e6668e06b2241fcf9d6253\" rel=\"nofollow noopener\" shape=\"rect\">Ontada<\/a>\u00ae at the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fconferences.asco.org%2Fam%2Fattend&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=2022+American+Society+of+Clinical+Oncology+%28ASCO%29+Annual+Meeting&amp;index=5&amp;md5=c1d7cd53fe62499924c65cfdeda7cfd8\" rel=\"nofollow noopener\" shape=\"rect\">2022 American Society of Clinical Oncology (ASCO) Annual Meeting<\/a>. The findings show that the incorporation of a remote oncology pharmacist in clinical research teams significantly enhanced patient enrollment for Protocol 2 of the MYLUNG Consortium.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220606005441\/en\/382659\/4\/TUSON_big_triangle.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220606005441\/en\/382659\/21\/TUSON_big_triangle.jpg\"><\/a><\/p>\n<p>\n\u201cAdvances in science are quickly enabling new treatment opportunities, but timely enrollment into clinical trials continues to be a challenge,\u201d said Elizabeth Koselke, PharmD, senior clinical pharmacist for The Network. \u201cOur study showed that by incorporating an oncology-trained clinical pharmacist to remotely review chemotherapy regimens and a customized recruitment report, we were able to more efficiently screen patients and significantly enhance Protocol 2 enrollment.\u201d\n<\/p>\n<p>\nKoselke presented the findings during an oral presentation at ASCO titled, \u201c<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmeetings.asco.org%2Fabstracts-presentations%2F208041&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Impact+of+oncology+clinical+pharmacist+intervention+on+clinical+trial+enrollment+in+The+US+Oncology+Network+%26%238217%3Bs+MYLUNG+Consortium&amp;index=6&amp;md5=9dec878b968d3864671665fe34b7da0f\" rel=\"nofollow noopener\" shape=\"rect\">Impact of oncology clinical pharmacist intervention on clinical trial enrollment in The US Oncology Network \u2019s MYLUNG Consortium<\/a>.\u201d\n<\/p>\n<p>\nIn the study, oncology-trained clinical pharmacists reviewed over an eight-month period 506 newly diagnosed and untreated NSCLC patients from six practices in The Network. Working remotely, the pharmacist reviewed chemotherapy regimen orders and identified, screened and assisted with recruitment of eligible patients for enrollment in MYLUNG Consortium Protocol 2. Working remotely enabled the pharmacists to identify patients quickly across the country who were potential candidates for the study. Enrollments and intervention data were then tracked to monitor the impact of the pharmacist intervention. The study showed that average monthly enrollment was significantly greater after pharmacist intervention (6.6 patients a month per practice) when compared to monthly enrollment before pharmacist intervention (3.4 patients a month per practice).\n<\/p>\n<p>\n\u201cThese data show that using an interdisciplinary approach to trial enrollment can be an effective method to increase speed and efficiency in real-world clinical research,\u201d noted Robert L. Coleman, MD, FACOG, FACS, chief scientific officer of US Oncology Research and the MYLUNG Consortium Principal Investigator. \u201cAs we move into Protocol 3 of the MYLUNG Consortium study, we look forward to continuing to validate pharmacist intervention across a wider spectrum of practices across The Network.\u201d\n<\/p>\n<p>\nAn additional study at ASCO 2022 took a further look at the MYLUNG Consortium Protocol 1 results that were first presented at ASCO 2021. These initial <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fusoncology.com%2Fnews%2Ffirst-phase-results-of-mylung-consortium-provide-historical-view-of-biomarker-testing-patterns-and-identify-data-gaps-for-ongoing-prospective-research%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=findings&amp;index=7&amp;md5=ac772da49183b6fe1e68c959eea1561b\" rel=\"nofollow noopener\" shape=\"rect\">findings<\/a> reported that fewer than 50 percent of metastatic non-small cell lung cancer patients had the recommended biomarker tests.\n<\/p>\n<p>\nIn a poster presentation titled, \u201c<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmeetings.asco.org%2Fabstracts-presentations%2F212846&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Predictors+of+biomarker+testing+among+patients+%28pts%29+with+metastatic+non-small+cell+lung+cancer+%28mNSCLC%29&amp;index=8&amp;md5=1547c9bf3b78ea041a799300d43e085f\" rel=\"nofollow noopener\" shape=\"rect\">Predictors of biomarker testing among patients (pts) with metastatic non-small cell lung cancer (mNSCLC)<\/a>,\u201d MYLUNG Consortium researchers examined the social and economic factors associated with biomarker undertesting. The research found that lower comprehensive biomarker testing rates were associated with patients who were of the African American race, seen in a smaller practice size or in a practice in the southern part of the United States, or had squamous cell histology.\n<\/p>\n<p>\n\u201cThis retrospective analysis took the previously reported research from Protocol 1 and further examined the patient factors that are associated with a lack of biomarker testing,\u201d said Dr. Nicholas Robert, chief medical officer of Ontada. \u201cUnderstanding these clinical and social determinants of health will be important interventions to improve testing rates as we enter into the prospective phases of the MYLUNG Consortium study.\u201d\n<\/p>\n<p>\nThe MYLUNG Consortium is a collaborative and innovative research study comprised of three protocols over a five-year period, enabled through a unique collaboration of various organizations and stakeholders working together across the spectrum of NSCLC drug development, therapy and care. The number of consortium participants continues to grow, all bringing unique perspectives to this innovative study. The MYLUNG Consortium brings together providers and researchers in The Network, US Oncology Research and Ontada with life sciences companies <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.amgen.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Amgen&amp;index=9&amp;md5=90c191f70475999e4c50737ec9ad6ec6\" rel=\"nofollow noopener\" shape=\"rect\">Amgen<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=AstraZeneca&amp;index=10&amp;md5=43ad02502a4664234c9c802fcc0af604\" rel=\"nofollow noopener\" shape=\"rect\">AstraZeneca<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lilly.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Eli+Lilly+and+Company&amp;index=11&amp;md5=8690c4f19730e8709f9ef68e0f078cb2\" rel=\"nofollow noopener\" shape=\"rect\">Eli Lilly and Company<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gene.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Genentech&amp;index=12&amp;md5=8fe8089c72abb1e6b4f7fba181f1a77f\" rel=\"nofollow noopener\" shape=\"rect\">Genentech<\/a> (a member of the Roche Group), and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.mirati.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Mirati+Therapeutics%2C+Inc&amp;index=13&amp;md5=6ab5f02d62a9eef387ac98a5b6c5cdcb\" rel=\"nofollow noopener\" shape=\"rect\">Mirati Therapeutics, Inc<\/a>. Patient advocacy groups <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Flungevity.org%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=LUNGevity&amp;index=14&amp;md5=eaefaf074715aae64521cd630b3226f9\" rel=\"nofollow noopener\" shape=\"rect\">LUNGevity<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fgo2foundation.org%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=GO2+Foundation+for+Lung+Cancer&amp;index=15&amp;md5=9b9da0ae73fc581b76a7bebd5dc4c17d\" rel=\"nofollow noopener\" shape=\"rect\">GO2 Foundation for Lung Cancer<\/a> are also participating, playing a key role in the study by keeping the focus on patients. Participating practices in The Network include <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fillinoiscancerspecialists.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Illinois+Cancer+Specialists&amp;index=16&amp;md5=386c9d1b51818b7244a6accc7e6fcb1d\" rel=\"nofollow noopener\" shape=\"rect\">Illinois Cancer Specialists<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmarylandoncology.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Maryland+Oncology+Hematology&amp;index=17&amp;md5=1583ecb78110ff473cf646363b38f6a8\" rel=\"nofollow noopener\" shape=\"rect\">Maryland Oncology Hematology<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmnoncology.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Minnesota+Oncology&amp;index=18&amp;md5=9a55f67f574d7132b654d354672b908b\" rel=\"nofollow noopener\" shape=\"rect\">Minnesota Oncology<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnewyorkoncology.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=New+York+Oncology+Hematology&amp;index=19&amp;md5=2f2bdfa586d4a4224682ec5d8895f561\" rel=\"nofollow noopener\" shape=\"rect\">New York Oncology Hematology<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ohcare.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Oncology+Hematology+Care&amp;index=20&amp;md5=6be7fe38c0f536ea51179635c90d9cbf\" rel=\"nofollow noopener\" shape=\"rect\">Oncology Hematology Care<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.rockymountaincancercenters.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Rocky+Mountain+Cancer+Centers&amp;index=21&amp;md5=229e2a29553a9797c360507d92905baf\" rel=\"nofollow noopener\" shape=\"rect\">Rocky Mountain Cancer Centers<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.texasoncology.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Texas+Oncology&amp;index=22&amp;md5=d465a616b6e65dbb86017e04ace6ff98\" rel=\"nofollow noopener\" shape=\"rect\">Texas Oncology<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.southerncancercenter.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Southern+Cancer+Center&amp;index=23&amp;md5=75e0db5daf678d47b8cc5ce9562e3429\" rel=\"nofollow noopener\" shape=\"rect\">Southern Cancer Center<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvirginiacancerspecialists.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Virginia+Cancer+Specialists&amp;index=24&amp;md5=a5142146d30e3096052f10a25b5d2468\" rel=\"nofollow noopener\" shape=\"rect\">Virginia Cancer Specialists<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvirginiacancer.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Virginia+Oncology+Associates&amp;index=25&amp;md5=8be8c8bf9eb2c43eb4269062df923b88\" rel=\"nofollow noopener\" shape=\"rect\">Virginia Oncology Associates<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.oregoncancer.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Willamette+Valley+Cancer+Institute+and+Research+Center&amp;index=26&amp;md5=d157aabbea7dc34ae4cc0078e27219a5\" rel=\"nofollow noopener\" shape=\"rect\">Willamette Valley Cancer Institute and Research Center<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwoodlandsmed.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Woodlands+Medical+Specialists&amp;index=27&amp;md5=cb94af9db4822c88a69bb3cfbaef45cc\" rel=\"nofollow noopener\" shape=\"rect\">Woodlands Medical Specialists<\/a>.\n<\/p>\n<p>\nRead more about the MYLUNG Consortium <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fusoncology.com%2Fan-inside-look-at-mylung%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=here&amp;index=28&amp;md5=36138fce5e094d1c29346b0d3dbca74b\" rel=\"nofollow noopener\" shape=\"rect\">here<\/a>. To schedule a media interview with one of the study investigators, contact Claire Crye at <a target=\"_blank\" href=\"&#x6d;&#97;&#105;l&#x74;&#x6f;&#58;C&#x6c;&#x61;&#105;r&#x65;&#x2e;&#67;r&#x79;&#x65;&#64;u&#x73;&#x6f;&#110;c&#x6f;&#x6c;&#111;&#103;y&#x2e;&#x63;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">Cla&#105;&#114;&#101;&#46;&#x43;&#x72;&#x79;&#x65;&#x40;&#x75;&#x73;onc&#111;&#108;&#111;&#103;&#121;&#x2e;&#x63;&#x6f;&#x6d;<\/a>.\n<\/p>\n<p>\n<b>About The US Oncology Network<\/b>\n<\/p>\n<p>\nEvery day, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.usoncology.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=The+US+Oncology+Network&amp;index=29&amp;md5=85efa59d6a61f1b43be29bf08b30cf3b\" rel=\"nofollow noopener\" shape=\"rect\">The US Oncology Network<\/a> (The Network) helps approximately 1,400 independent physicians deliver value-based, integrated care to patients \u2014 close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure and support of <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mckesson.com&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=McKesson+Corporation&amp;index=30&amp;md5=da296b90dda0f67033aad2570cdfecaf\" rel=\"nofollow noopener\" shape=\"rect\">McKesson Corporation<\/a>. This collaboration allows the providers in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere.\n<\/p>\n<p>\n<b>About US Oncology Research<\/b>\n<\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fusoncology.com%2Fphysicians%2Fclinical-trials%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=US+Oncology+Research&amp;index=31&amp;md5=ed0eb705e73793604bec2698ae35d1b3\" rel=\"nofollow noopener\" shape=\"rect\">US Oncology Research<\/a> draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. US Oncology Research serves approximately 60 research sites and 170 locations, managing about 500 active trials at any given time. For the past 20 years, physicians in the research network have enrolled more than 91,000 patients in approximately 2,000 trials and have played a role in over 100 FDA-approved cancer therapies. US Oncology Research is supported by <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mckesson.com&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=McKesson+Corporation&amp;index=32&amp;md5=691849d881265803a6b0da95e405127c\" rel=\"nofollow noopener\" shape=\"rect\">McKesson Corporation<\/a>.\n<\/p>\n<p>\n<b>About Ontada<\/b>\n<\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ontada.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=Ontada&amp;index=33&amp;md5=c212fc09d08d7e40eb047744e139e4bc\" rel=\"nofollow noopener\" shape=\"rect\">Ontada<\/a>\u00ae is an oncology real-world data and evidence, clinical education and provider technology business dedicated to transforming the fight against cancer. Part of <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.mckesson.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=McKesson+Corporation&amp;index=34&amp;md5=59423a2e949164a1e9427ea919739648\" rel=\"nofollow noopener\" shape=\"rect\">McKesson Corporation<\/a>, we support science through our data, technology and channels, which accelerate innovation for life science companies, support the education of community oncology providers and advance patient care. Together with our partners, we improve the lives of cancer patients. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ontada.com%2F&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=ontada.com&amp;index=35&amp;md5=fc0d4efd2abf6cae684799a16e40627b\" rel=\"nofollow noopener\" shape=\"rect\">ontada.com <\/a>or follow <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fontadaoncology&amp;esheet=52739954&amp;newsitemid=20220606005441&amp;lan=en-US&amp;anchor=%40OntadaOncology&amp;index=36&amp;md5=1358ad946bdb440bd43d6494d15e5678\" rel=\"nofollow noopener\" shape=\"rect\">@OntadaOncology<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nThe US Oncology Network<br \/>\n<br \/>Claire Crye, Public Relations<br \/>\n<br \/>281.825.9927 <a target=\"_blank\" href=\"&#x6d;&#97;&#x69;&#108;t&#x6f;&#58;c&#x6c;&#97;&#x69;&#x72;e&#x2e;&#99;r&#x79;&#101;&#x40;&#x75;s&#x6f;&#110;c&#x6f;&#108;o&#x67;&#121;&#x2e;&#99;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#99;&#x6c;&#97;&#x69;&#114;&#x65;&#46;&#x63;&#114;&#x79;&#101;&#x40;&#117;&#x73;&#111;&#x6e;&#99;&#x6f;&#108;&#x6f;&#103;&#x79;&#46;&#x63;&#111;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Average monthly enrollment nearly doubled with pharmacy intervention Remote pharmacist easily adapted into clinic workflows in community practices THE WOODLANDS, Texas&#8211;(BUSINESS WIRE)&#8211;Results from the second phase of the broad, collaborative MYLUNG ConsortiumTM research study in non-small cell lung cancer (NSCLC) were presented by The US Oncology Network (The Network), US Oncology Research and Ontada\u00ae at &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44775","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New MYLUNG Consortium Research Demonstrates Remote Pharmacist Intervention Significantly Increases Clinical Trial Enrollments in Community Oncology Setting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New MYLUNG Consortium Research Demonstrates Remote Pharmacist Intervention Significantly Increases Clinical Trial Enrollments in Community Oncology Setting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Average monthly enrollment nearly doubled with pharmacy intervention Remote pharmacist easily adapted into clinic workflows in community practices THE WOODLANDS, Texas&#8211;(BUSINESS WIRE)&#8211;Results from the second phase of the broad, collaborative MYLUNG ConsortiumTM research study in non-small cell lung cancer (NSCLC) were presented by The US Oncology Network (The Network), US Oncology Research and Ontada\u00ae at ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-06T22:01:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220606005441\/en\/382659\/21\/TUSON_big_triangle.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"New MYLUNG Consortium Research Demonstrates Remote Pharmacist Intervention Significantly Increases Clinical Trial Enrollments in Community Oncology Setting\",\"datePublished\":\"2022-06-06T22:01:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\\\/\"},\"wordCount\":1030,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220606005441\\\/en\\\/382659\\\/21\\\/TUSON_big_triangle.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\\\/\",\"name\":\"New MYLUNG Consortium Research Demonstrates Remote Pharmacist Intervention Significantly Increases Clinical Trial Enrollments in Community Oncology Setting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220606005441\\\/en\\\/382659\\\/21\\\/TUSON_big_triangle.jpg\",\"datePublished\":\"2022-06-06T22:01:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220606005441\\\/en\\\/382659\\\/21\\\/TUSON_big_triangle.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220606005441\\\/en\\\/382659\\\/21\\\/TUSON_big_triangle.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New MYLUNG Consortium Research Demonstrates Remote Pharmacist Intervention Significantly Increases Clinical Trial Enrollments in Community Oncology Setting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New MYLUNG Consortium Research Demonstrates Remote Pharmacist Intervention Significantly Increases Clinical Trial Enrollments in Community Oncology Setting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/","og_locale":"en_US","og_type":"article","og_title":"New MYLUNG Consortium Research Demonstrates Remote Pharmacist Intervention Significantly Increases Clinical Trial Enrollments in Community Oncology Setting - Pharma Trend","og_description":"Average monthly enrollment nearly doubled with pharmacy intervention Remote pharmacist easily adapted into clinic workflows in community practices THE WOODLANDS, Texas&#8211;(BUSINESS WIRE)&#8211;Results from the second phase of the broad, collaborative MYLUNG ConsortiumTM research study in non-small cell lung cancer (NSCLC) were presented by The US Oncology Network (The Network), US Oncology Research and Ontada\u00ae at ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-06T22:01:22+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220606005441\/en\/382659\/21\/TUSON_big_triangle.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"New MYLUNG Consortium Research Demonstrates Remote Pharmacist Intervention Significantly Increases Clinical Trial Enrollments in Community Oncology Setting","datePublished":"2022-06-06T22:01:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/"},"wordCount":1030,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220606005441\/en\/382659\/21\/TUSON_big_triangle.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/","url":"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/","name":"New MYLUNG Consortium Research Demonstrates Remote Pharmacist Intervention Significantly Increases Clinical Trial Enrollments in Community Oncology Setting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220606005441\/en\/382659\/21\/TUSON_big_triangle.jpg","datePublished":"2022-06-06T22:01:22+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220606005441\/en\/382659\/21\/TUSON_big_triangle.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220606005441\/en\/382659\/21\/TUSON_big_triangle.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/new-mylung-consortium-research-demonstrates-remote-pharmacist-intervention-significantly-increases-clinical-trial-enrollments-in-community-oncology-setting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"New MYLUNG Consortium Research Demonstrates Remote Pharmacist Intervention Significantly Increases Clinical Trial Enrollments in Community Oncology Setting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44775"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44775\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}